Cargando…
Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]
BACKGROUND: Fatigue is a major clinical problem in many patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined. Recently, a large proportion of patients with these diseases was found to have symptoms of depression. Because...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC481069/ https://www.ncbi.nlm.nih.gov/pubmed/15251034 http://dx.doi.org/10.1186/1471-230X-4-13 |
_version_ | 1782121650945261568 |
---|---|
author | ter Borg, Pieter CJ van Os, Erik van den Broek, Walter W Hansen, Bettina E van Buuren, Henk R |
author_facet | ter Borg, Pieter CJ van Os, Erik van den Broek, Walter W Hansen, Bettina E van Buuren, Henk R |
author_sort | ter Borg, Pieter CJ |
collection | PubMed |
description | BACKGROUND: Fatigue is a major clinical problem in many patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined. Recently, a large proportion of patients with these diseases was found to have symptoms of depression. Because fatigue is a frequent symptom of depression and there is some evidence that treatment with an antidepressant improves fatigue in patients with fibromyalgia, we hypothesised that the antidepressant fluvoxamine might improve fatigue related to PBC and PSC. METHODS: Fatigued patients were randomised to receive fluvoxamine (75 mg BID) or placebo for a six-week period. Fatigue and quality of life were quantified using a visual analogue scale, the Fisk Fatigue Severity Scale, the Multidimensional Fatigue Inventory and the SF-36. RESULTS: Seventeen and 16 patients were allocated to fluvoxamine and placebo, respectively. There was no statistically significant beneficial effect of fluvoxamine on fatigue or quality of life. The median VAS scores in the fluvoxamine and placebo groups were 7.40 and 7.45 at day 0, 6.9 and 7.15 at day 14, 7.45 and 7.65 at day 42 and 7.8 and 8.0 four weeks after treatment discontinuation. CONCLUSION: We found no evidence for a beneficial effect of fluvoxamine on fatigue in these patients with cholestatic liver disease and severe chronic fatigue. |
format | Text |
id | pubmed-481069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-4810692004-07-23 Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] ter Borg, Pieter CJ van Os, Erik van den Broek, Walter W Hansen, Bettina E van Buuren, Henk R BMC Gastroenterol Research Article BACKGROUND: Fatigue is a major clinical problem in many patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined. Recently, a large proportion of patients with these diseases was found to have symptoms of depression. Because fatigue is a frequent symptom of depression and there is some evidence that treatment with an antidepressant improves fatigue in patients with fibromyalgia, we hypothesised that the antidepressant fluvoxamine might improve fatigue related to PBC and PSC. METHODS: Fatigued patients were randomised to receive fluvoxamine (75 mg BID) or placebo for a six-week period. Fatigue and quality of life were quantified using a visual analogue scale, the Fisk Fatigue Severity Scale, the Multidimensional Fatigue Inventory and the SF-36. RESULTS: Seventeen and 16 patients were allocated to fluvoxamine and placebo, respectively. There was no statistically significant beneficial effect of fluvoxamine on fatigue or quality of life. The median VAS scores in the fluvoxamine and placebo groups were 7.40 and 7.45 at day 0, 6.9 and 7.15 at day 14, 7.45 and 7.65 at day 42 and 7.8 and 8.0 four weeks after treatment discontinuation. CONCLUSION: We found no evidence for a beneficial effect of fluvoxamine on fatigue in these patients with cholestatic liver disease and severe chronic fatigue. BioMed Central 2004-07-13 /pmc/articles/PMC481069/ /pubmed/15251034 http://dx.doi.org/10.1186/1471-230X-4-13 Text en Copyright © 2004 ter Borg et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article ter Borg, Pieter CJ van Os, Erik van den Broek, Walter W Hansen, Bettina E van Buuren, Henk R Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title | Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title_full | Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title_fullStr | Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title_full_unstemmed | Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title_short | Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634] |
title_sort | fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [isrctn88246634] |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC481069/ https://www.ncbi.nlm.nih.gov/pubmed/15251034 http://dx.doi.org/10.1186/1471-230X-4-13 |
work_keys_str_mv | AT terborgpietercj fluvoxamineforfatigueinprimarybiliarycirrhosisandprimarysclerosingcholangitisarandomisedcontrolledtrialisrctn88246634 AT vanoserik fluvoxamineforfatigueinprimarybiliarycirrhosisandprimarysclerosingcholangitisarandomisedcontrolledtrialisrctn88246634 AT vandenbroekwalterw fluvoxamineforfatigueinprimarybiliarycirrhosisandprimarysclerosingcholangitisarandomisedcontrolledtrialisrctn88246634 AT hansenbettinae fluvoxamineforfatigueinprimarybiliarycirrhosisandprimarysclerosingcholangitisarandomisedcontrolledtrialisrctn88246634 AT vanbuurenhenkr fluvoxamineforfatigueinprimarybiliarycirrhosisandprimarysclerosingcholangitisarandomisedcontrolledtrialisrctn88246634 |